Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948617 | 1.00 | BRD4 (0.38) | BRD4ALDH1A1 | |
| SCHEMBL6906430 | 0.85 | BRD4 (0.34) | BRD4 | |
| SCHEMBL6906522 | 0.81 | FYN (0.36) | BRD4 | |
| SCHEMBL8621104 | 0.79 | BRD4 (0.36) | BRD4 | |
| SCHEMBL11502462 | 0.78 | — | — | |
| SCHEMBL4123768 | 0.74 | — | — | |
| SCHEMBL6908499 | 0.73 | BRD4 (0.31) | BRD4 | |
| SCHEMBL6906224 | 0.70 | MME (0.32) | — | |
| SCHEMBL6904948 | 0.69 | TLR4 (0.36) | ALDH1A1 | |
| SCHEMBL13428636 | 0.67 | BRD4 (0.38) | BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284741-B1 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET INC (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1964569-A2 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections | Pharmasset, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7094770-B2 | 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections | PHARMASSET, LTD. (BB) | 2006-08-22 | — | — | US | disclosed |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET, INC. | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | HCCS, HDGF, HMBS | BRD4 1520/4885ALDH1A1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.